Ilginatinib - Nippon Shinyaku
Alternative Names: NS 018Latest Information Update: 10 Sep 2024
Price :
$50 *
At a glance
- Originator Nippon Shinyaku
- Developer Nippon Shinyaku; NS Pharma
- Class Antineoplastics; Pyrazines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Janus kinase 2 inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological disorders; Myelofibrosis
Most Recent Events
- 10 Sep 2024 Discontinued - Phase-II for Myelofibrosis in United Kingdom, Turkey, Poland, Italy, Germany, Thailand, South Korea, Malaysia (PO) (Nippon Shinyaku pipeline, September 2024)
- 06 Jun 2024 NS Pharma and Nippon Shinyaku terminates a phase-II trial in Myelofibrosis in USA, Malaysia, South Korea, Thailand, Italy, Turkey, Poland, UK and Germany (PO) due to business decision (NCT04854096) (EudraCT2021-000369-34)
- 08 Aug 2023 Ilginatinib receives Orphan Drug status for Myelofibrosis in European Union